Compositions comprising bacterial strains
The invention provides compositions comprising one or more bacterial strains for treating preventing diarrhea and/or constipation.
1. A method of treating diarrhea, constipation, or diarrhea and constipation in a subject in need thereof, comprising administering to the subject a composition comprising: a bacteria strain, wherein the bacteria strain comprises a polynucleotide sequence of a 16S rRNA gene that has at least 95% sequence identity to SEQ ID NO:5, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12, a gap extension penalty of 2, and a Blocks Substitution Matrix (BLOSUM) of 62.
2. The method of claim 1 , wherein the subject is human.
3. The method of claim 1 , wherein the administering is oral.
4. The method of claim 1 , wherein the composition is a solid composition.
5. The method of claim 1 , wherein the bacteria strain is active.
6. The method of claim 1 , wherein the composition comprises an antioxidant.
7. The method of claim 1 , wherein the composition comprises from about 1×10 9 to about 1×10 12 CFU of the bacteria strain.
8. The method of claim 1 , wherein the composition comprises from about 1×10 3 to about 1×10 11 CFU/g of the bacteria strain with respect to a total weight of the composition.
9. The method of claim 1 , wherein the subject has one or more of irritable bowel syndrome, Crohn's disease, ulcerative colitis, functional dyspepsia, gastroenteritis, urinary tract infection, and neonatal meningitis.
10. The method of claim 1 , wherein the subject has diarrhea and not constipation.
11. The method of claim 1 , wherein the subject has constipation and not diarrhea.
12. The method of claim 1 , wherein the subject has diarrhea and constipation.
13. The method of claim 1 , further comprising administering an additional therapeutic agent to the subject.
14. The method of claim 1 , wherein at least 50% of the bacteria strain as measured by an amount of CFU, remains viable after about 1 year of storage when the composition is stored in a closed container at 25° C. at 95% relative humidity.
15. The method of claim 1 , wherein the administering reduces a level of hydrogen gas in a breath of the subject by at least 40 ppm, relative to a level of hydrogen gas prior to the administering, as determined by a hydrogen breath test.
16. The method of claim 1 , wherein the composition is a pharmaceutical composition.
17. The method of claim 16 , wherein the pharmaceutical composition is comprised in one or more enteric capsules.